NSB Market Cap $ 23 million Very well Funded Option Expiry this week . Safety and Toxicity Report to be completed and to be reported this quarter and to Commence Phase 1 next quarter . Great Interview at Stock Head , definitely a salesman which is extremely important in small caps early on to generate interest. Safety and Toxicity as well as Phase 1 studies are going to be conservative with a small cohort of Patients .Phase 2a, 2b is where its get much more difficult as your dealing with a larger cohort of patients , dosages , patients with different levels of damage , demographics , etc . It is completely different in terms of risk as an investor or trader .
